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1 INTRODUCTION  
1.1 The blood-brain barrier 
The blood-brain barrier (BBB) is formed by microvascular endothelial cells to separate 
blood from brain parenchyma (Abbott et al., 2010). It is the largest interface between the 
central nervous system (CNS) and the periphery, covering 12-18m
2
 total area of exchange 
between the circulating blood and the brain in an average human adult brain (Abbott et 
al., 2010). 
Acting as a physical, metabolic and transport barrier, the BBB not only preserves the 
homeostatic environment essential for neurons by providing a stable ionic composition 
necessary for optimal neuronal function, but also ensures sufficient nutrient supply and 
the separation of neurotransmitter pools between the central and the peripheral nervous 
system (Abbott et al., 2010; Bernacki et al., 2008). Moreover, the BBB protects the brain 
from potentially neurotoxic substances of endogenous or xenobiotic origin (Abbott et al., 
2010). 
1.1.1 Cell types at the BBB - the neurovascular unit 
The BBB is primarily formed by the endothelial cells of cerebral vessels. These 
endothelial cells differ in their characteristics from endothelial cells in other organs, since 
they lack fenestration, show low transcytotic activity and the presence of tight junctions 
(TJ) (Hawkins and Davis, 2005). The surface of the endothelial cells is negatively 
charged, facilitating transport of positively charged molecules. In addition, endothelial 
cells in the BBB have a greater number of mitochondria (Cardoso et al., 2010; Abbott et 
al., 2010; Persidsky et al., 2006). The higher number of mitochondria elevates the energy 
potential of the endothelial cells providing the energy required to actively transport 
nutrients into the brain and potentially harmful substances out of the brain (Persidsky et 
al., 2006). 
However, the regulation of the barrier characteristics is not entirely determined by the 
endothelial cells, but rather is an interaction of different cells types present at the interface 
of blood and brain, suggesting that these cells form a functional unit that is referred to as 
the neurovascular unit (NVU). The NVU consists of the endothelial cells, astrocytic glia 
cells, pericytes, the basement membrane and the neurons (Hawkins and Davis, 2005; 
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Cardoso et al., 2010) (Figure 1). 
Astrocytes are glial cells whose end-feet envelop the walls of the endothelium. This close 
contact enables them to be involved in the modulation and induction of BBB properties 
(Abbott, 2002), while gap junctions between neighbouring astrocyte processes permit 
communication with other astrocytes (Abbott et al., 2006). In vitro studies have shown 
that astrocytes play an important role in many processes, for example up-regulating 
enzymes, tight junctions and the polarized expression of transporters like P-glycoprotein 
(P-gp) and glucose transporter GLUT-1 (Abbott et al., 2006). Furthermore, astrocytes 
contribute to the specific ionic, amino acid and water homeostasis required for proper 
brain function (Abbott et al., 2006). 
 
Research has shown that areas of the endothelium that lack astrocyte envelopment, still 
express specific BBB characteristics leading to the suggestion that astrocytes are able to 
secret soluble factors (Cardoso et al., 2010). These factors include transforming growth 
factor ß (TGFß), glial-derived neurotrophic factor (GDNF), basic fibroblast growth factor 
(bFGF) and angiopoetin 1 (ANG1), which have all been shown to improve BBB 
properties in vitro (Abbott et al., 2006). 
Figure 1: Schematic representation of the constituents of the 
neurovascular unit (modified from Abbott et al., 2006) 
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Pericytes are another constituent of the NVU. Pericytes are vascular smooth muscle cells 
that are spread discontinuously along the capillaries and in part surround the endothelium 
(Abbott et al., 2010). Via their cellular projections and gap junctions, pericytes are in 
close contact with the endothelial cells in vivo and have been shown to induce BBB 
properties in vitro such as increased tightness of the barrier and up-regulation of P-gp 
(Nakagawa et al., 2007). Moreover, pericytes have been found to migrate away from 
microvessels as a consequence of hypoxia or traumatic brain injury, both associated with 
barrier disruption, which further points to their involvement in maintaining barrier 
function (Cardoso et al., 2010; Persidsky et al., 2006). 
The basement membrane, that engulfs pericytes and endothelial cells, consists of collagen 
type IV, elastin, fibrillin, laminin and fibronectin in addition to cell adhesion molecules 
(CAM) and signalling proteins (Carvey et al., 2009). Endothelial cells, pericytes and 
astrocytes are all involved in the synthesis of this complex matrix, which acts as an 
anchor keeping these cells in place. Furthermore, the basement membrane is involved in 
the regulation of cellular functions and TJ expression through the activation of signalling 
proteins on the surface of the endothelial cells (Carvey et al., 2009; Hawkins and Davis, 
2005). Thus, alterations or disruption of the basement membrane have been shown to be 
connected with loss of BBB integrity in pathological conditions (Hawkins and Davis, 
2005). 
1.1.2 Intercellular junctions - the BBB as a physical barrier 
The presence of intercellular junctions like tight junctions (TJ) and adherens junctions 
(AJ) give the BBB its characteristic properties, considering that these structures not only 
severely restrict paracellular transport of compounds circulating in the blood from 
entering the brain (physical barrier) but also separate the apical from the basal domain, 
necessary for the polarized expression of transporters (transport barrier) (Abbott et al., 
2006). 
The TJ are formed by 3 transmembrane protein families: occludin, claudin and junction 
associated molecules (JAM).These proteins interact with cytoplasmic proteins like zonula 
occludens proteins (ZO), linking the TJ proteins to the components of the cytoskeleton 
(Weiss et al., 2009; Abbott et al., 2010) (Figure 2). 
Occludin is a 65 kDa protein with 4 transmembranous domains, 2 extracellular loops and 
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the N- and C-terminal domains both situated in the cytoplasm. The extracellular loops 
enable occludin to span the intracellular cleft (Hawkins and Davis, 2005; Persidsky et al., 
2006) and this consequently contributes to the formation of tight junction and regulation 
of paracellular permeability (Persidsky et al., 2006). However, in experiments with 
knock-out mice it was demonstrated that occludin is not essential for TJ formation, even 
though decreased expression of occludin is connected to loss of barrier integrity in 
pathological conditions (Hawkins and Davis, 2005). Thus, it is believed that occludin 
enhances the restrictiveness of the TJ, yet claudins are the components responsible for the 
establishment of the barrier properties (Wolburg and Lippoldt, 2002; Hawkins and Davis, 
2005). 
 
Claudins are 20-24 kDa proteins, that like occludin, have 4 transmembranous domains 
and 2 extracellular loops (Hawkins and Davis, 2005; Abbott et al., 2006), but do not share 
any sequence homology with occludin (Wolburg and Lippoldt, 2002). The extracellular 
loops mediate homophilic and heterophilic interaction between adjacent cells (Hawkins 
and Davis, 2005). These interactions are responsible for the severe restriction of 
movement for water-soluble molecules via the paracellular pathway, forcing the 
molecules to move through the membranes and the cytosol (Bernacki et al., 2008). 
 
Figure 2: Schematic representation of the structure of the tight junctions at the blood-brain 
barrier (from Abbott et al., 2010) 
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Both claudin and occludin bind to accessory proteins such as the zonola occludens 
proteins (ZO 1-3) to connect the transmembranous TJ proteins with the actin cytoskeleton 
(Abbott et al., 2006). These scaffolding proteins are also responsible for the recruitment 
of various signalling proteins and transcription factors to the TJ (Terry et al., 2010; Abbott 
et al., 2006). ZOs together with Ca
2+ dependent serine protein kinase (CASK) are 
considered first order adaptor proteins and second order adaptor proteins include cingulin 
as well as junction-associated coiled-coil protein (JACOP) (Abbott et al., 2006). In 
addition to the presence of occludin and claudin at the TJ of the BBB, junction adhesion 
molecules (JAMs) also contribute to the formation of the TJ (Abbott et al., 2006) as well 
as being involved in leukocyte migration (Cardoso et al., 2010). JAMs belong to the IgG 
superfamily and in contrast to occludin and claudin have only one transmembranous 
domain (Persidsky et al., 2006; Bernacki et al., 2008). 
Below the TJ, adherens junctions (AJ) are formed to further stabilize cell-cell interactions 
and to give structural support (Abbott et al, 2006). AJ are believed to play a role in the 
maintenance of the barrier function, since AJ disruption can lead to increased 
permeability (Abbott et al., 2010). The AJ are composed of the transmembranous proteins 
vascular endothelial cadherin (VE cadherin) and platelet-endothelial cell adhesion 
molecule (PECAM), which are linked to the cytoskeleton via the scaffolding proteins of 
the catenin family (alpha, beta and gamma) and the protein desmoplakin is also involved 
in the process (Abbott et al., 2006). 
However, the TJ must not be regarded as a static element but as a dynamic structure that 
can be modulated (e.g. phosphorylation of TJ proteins) according to different stimuli like 
oxidative stress, vasogenic agents and inflammatory mediators (Cardoso et al., 2010). TJs 
can be opened or tightened through various pathways including protein kinases, members 
of the mitogen-activated protein kinase family (MAPK), endothelial nitric oxide synthase 
(eNOS), G-proteins and signalling pathways involving Ca
2+
 as a second messenger 
(Cardoso et al., 2010). The signalling at the TJs is a bi-directional process with the signal 
forwarded from the inside of the endothelial cells to the TJ proteins as well as TJ proteins 
transmitting information back to the endothelial cells. This results in the regulation of 
gene expression leading to cellular responses like proliferation and differentiation (Terry 
et al., 2010). 
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1.1.3 The BBB as a metabolic barrier 
The expression of intra- and extracellular enzymes at the BBB is responsible for its role 
as a metabolic barrier and are produced by both endothelial and astrocytic cells. Enzyme 
concentrations are high, when compared to noncerebral endothelial cells (Persidsky et al., 
2006) and include monoamine oxidase, gamma-glutamyl transpeptidase, alkaline 
phosphatase, cytochrome P450 enzymes and several other peptidases and nucleotidases 
(Cecchelli et al., 2007; Abbott et al., 2006). 
1.1.4 Transport across the BBB - the BBB as a transport barrier 
Depending on its characteristics, a molecule can enter the brain via several different 
routes of transport across the BBB (Figure 3).  
Due to the restrictive nature of the tight junction at the BBB, transport across the BBB is 
limited especially for water-soluble molecules, consequently isolating the brain from 
essential nutrients like glucose and amino acids (Abbott et al., 2010). In order to ensure 
adequate brain nutrition, specific solute carrier transporters (SLC) are expressed by the 
endothelial cells to facilitate their entry, since these polar nutrients cannot passively 
diffuse through the cell membranes (Abbott et al., 2010). Their expression can be either at 
the luminal and/ or at the abluminal side, regulating transport across the endothelium 
either into or out of the brain respectively (Abbott et al., 2010). Over 40 different families 
of SLC have been indentified so far (Eyal et al., 2009). Among these are several amino 
acid transporters like the LAT1 (for large neutral amino acids), as well as the organic 
anionic and cationic transporters (OAT, OCT), the glutamate transporter EAAT 
(excitatory amino acid transporter) and several transporters for nucleosides and 
nucleotides (Abbott et al., 2006; Bernacki et al.,2008; Eyal et al., 2009). Importantly, 
there is also a high expression of the glucose transporter GLUT-1 to supply glucose to the 
brain and its expression is modulated according to metabolic demands (Xiuli et al., 2003).  
Oxygen and carbon dioxide on the other hand can diffuse freely through the membranes 
along their concentration gradients, hence the oxygen supply and the carbon dioxide 
removal is entirely dependent on blood flow (Abbott et al., 2010). 
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Macromolecules such as peptides and proteins take the route of receptor-mediated (RMT) 
or absorptive mediated transcytosis (AMT) across the BBB (Abbott et al., 2010). In the 
case of RMT, after binding to the receptor the macromolecule is internalised with its 
receptor, transferred across the cell in a vesicle, and exocytosed on the abluminal 
membrane, during which it is presumed that there is a dissociation of the macromolecule 
from its receptor (Abbott et al., 2010). On the other hand, AMT requires a positively 
charged macromolecule interacting with the negatively charged surface of the membrane, 
which triggers the endocytotic process. Substrates for RMT include insulin, transferrin, 
lipoproteins, IgG and TNFα, whereas cationised albumin and other plasma proteins are 
examples for transport via AMT (Abbott et al., 2010). 
 
Lipid-soluble molecules, in contrast to macromolecules and water-soluble molecules can 
in principle diffuse freely across the BBB along their concentration gradient. The more 
lipid-soluble a compound is, the more likely it is to enter the brain successfully. However, 
their ability to do so is often lower than expected from their physicochemical properties 
due to the presence of efflux pumps at the BBB, known as ABC Transporters (ATP-
binding Cassette) (Abbott et al., 2010). 
 
Figure 3: Schematic representation of transport across the blood-brain barrier  
(from Abbott et al., 2010) 
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ABC transporters utilize energy supplied by ATP hydrolysis to actively efflux potentially 
neurotoxic substances, of either endogenous or xenobiotic origin, out of the brain 
(Löscher and Potschka 2005a). A total of 48 families of ABC transporters divided into 7 
subfamilies are known in humans of which P-glycoprotein (P-gp, ABC B1) is the best 
characterized (Begley, 2004; Leslie et al., 2005). P-gp was first discovered in association 
with drug resistance of tumour cells (Eyal et al., 2009; Löscher and Potschka, 2005b) and 
is a 170 kDa  glycoprotein with 12 transmembranous domains and 2 intracellular binding 
sites for ATP (Begley, 2004). P-gp is expressed at the luminal side of the BBB (Begley 
2004) and substrates include cytostatics (e.g. anthracyclines, vinca alkaloids, and 
taxanes), antiepileptic drugs (e.g. phenobarbital and carbamazepine) and protease 
inhibitors (e.g. indinavir and nelfinavir) (Löscher and Potschka, 2005b). 
Other members of the ABC transporter family include the multidrug resistance associated 
proteins (MRPs, ABC C family), which can be located either in the luminal or abluminal 
membrane of the endothelial cells (Eyal et al., 2009; Begley, 2004, Löscher and Potschka 
2005a) and the breast cancer resistance protein (BCRP), which is located in the luminal 
membrane (Eyal et al., 2009). Contrary to P-gp, MRPs favour anionic compounds and 
neutral compounds that are conjugated to glutathione, glucuronate or sulphate as 
substrates (Borst et al., 2000). An overlap with substrates for P-gp exists as well as there 
is a partial overlap for BCRP and P-gp substrates (Begley, 2004; Löscher and Potschka 
2005b; Eyal et al., 2009). 
The ability of ABC transporters to efflux a wide range of structurally and functionally 
diverse compounds out of the brain presents a major problem for the effective delivery of 
drugs into the CNS. This has led to the idea of modulating the BBB by using inhibitors 
for efflux pumps, like verapamil or cyclosporin A for P-gp (Löscher and Potschka, 
2005b). However, the risks involved in modulating these efflux pumps must clearly be 
kept in mind (Löscher and Potschka, 2005b). 
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1.2 Models to measure and predict BBB permeability 
In order to effectively treat a disease, a drug is required to reach the desired 
pharmacological target. In the case of a CNS related disease, the drug must be able to get 
into the brain, therefore it is necessary to cross the blood-brain barrier (BBB). Models to 
asses BBB permeability can be categorized as in vivo, in vitro and in silico models and 
each have their strengths and limitations (Mensch et al., 2009). 
1.2.1 In vivo 
In vivo methods still provide the most reliable information for testing and validating other 
models (Abbott, 2004), even though the techniques involved are both cost and labour 
intensive. Brain uptake can be measured according to two methodological approaches: 
equilibrium state based approaches to measure the extent of brain penetration and the 
brain/plasma ratio or approaches based on kinetic parameters, which aim to determine the 
rate of brain penetration and the permeability x surface product (Mensch et al., 2009). For 
this purpose either non-invasive or invasive techniques can be applied.  
Non-invasive techniques include PET (positron emission tomography) and MRI 
(magnetic resonance imaging), which can also be applied in humans and allow individual 
time course studies for brain uptake. These methods are highly sensitive, but since their 
use is expensive and the preparation and stability of the tracer substances can present a 
difficulty, these techniques are not used in routine drug screening (Mensch et al., 2009). 
Intravenous injection, brain uptake index and in situ brain perfusion are invasive 
techniques to measure brain uptake and involve the injection of the test compound, which 
is usually radiolabelled. In contrast to the intravenous injection, the brain uptake index 
technique uses a single injection directly into the carotid artery of the animal, hence 
avoiding systemic recirculation. The animal is decapitated after 15s and the amount of 
test compound in the brain is determined (Mensch et al., 2009; Bickel, 2005). The in situ 
brain perfusion uses longer perfusion times, between 60s and 60min, which makes it 
more sensitive and additionally the flow rate as well as the ionic composition of the 
perfusate can be adjusted (Bickel, 2005; Mensch et al., 2009). The perfusate is injected 
into the external carotid artery, which has been ligated with all the branches of the internal 
carotid artery prior to injection. This set up eliminates the disadvantages of the brain 
uptake index as it limits systemic circulation and metabolism (Mensch et al., 2009).  
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Though intracerebral microdialysis is also an invasive technique it can be performed on 
live animals, which is a great advantage. A probe with a semipermeable membrane is 
implanted into the brain of the animal and perfused with a physiological solution. The test 
compound is administered orally, subcutaneously or intravenously and, if able to enter the 
brain, can diffuse into the perfusate along its concentration gradient, where the 
concentration can be determined. Nevertheless, the implantation of the probe can damage 
the BBB and compromise its functionality (Mensch et al., 2009). 
1.2.2 In vitro  
In vitro models are simplifications of the in vivo situation, but are usually less labour 
intensive compared to in vivo models. An in vitro model should be robust, reproducible 
and most importantly needs to mimic the in vivo conditions as closely as possible. This 
should be in regard to the specific characteristics of the BBB, such as its morphology, 
presence of tight junctions (TJ) and expression of transporters and enzymes (Cecchelli et 
al., 2007). 
To assess the quality of the model two factors are usually referred to: the transendothelial 
electrical resistance (TEER) and the permeability of tracer substances. The TEER 
presents a good indication of the integrity and tightness of the barrier to small ions and 
the measurements can be easily and quickly carried out (Gumbleton and Audus, 2001). 
While TEER measurements alone might only provide limited information on the barrier 
properties, together with the permeability measurements of tracer substances it is possible 
to determine the development of a restrictive barrier (Gumbleton and Audus, 2001). 
These tracer substances must not be substrates for either uptake or efflux transporters and 
are fluorescent- or radiolabelled. Sodium fluorescein, fluorescent-labelled dextrans and 
radiolabelled sucrose, inulin and mannitol are most commonly used (Deli et al., 2005).  
Several different in vitro models, originating from different species and tissues, have been 
studied and discussed in the literature as potential BBB models, but there is yet no “gold 
standard” for a BBB in vitro model, hence the choice of the model depends on the study 
question (Abbott, 2004). 
1.2.2.1 Cells from noncerebral origin 
Cell lines from noncerebral origin have been tested to serve as surrogate BBB models 
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(Abbott, 2004), but usually fail due to insufficient barrier properties (Mensch et al., 
2009). The MDCK (Madin-Darby-Canine Kidney) shows high TEER values and low 
sucrose permeability and can furthermore be transfected with the MDR1 gene to achieve 
the polarized P-gp expression (Mensch et al., 2009). In spite of this, the MDCK cell line 
differs in gene expression, cell morphology and cell-cell junctions from brain endothelial 
cells (Cecchelli et al., 2007). The ECV304 cell line, which originates from a bladder 
carcinoma and shows epithelial and endothelial properties, and the Caco-2 cell line, 
which is derived from a human colon adenoma and is widely used in the industry as a 
well-established in vitro model for intestinal absorption, have both been dismissed as 
suitable BBB models for similar reasons (Cecchelli et al., 2007; Mensch et al., 2009). 
1.2.2.2 Brain endothelial cells 
1.2.2.2.1 Primary and low-passage endothelial cells 
Endothelial cells from brain microvessels can be isolated and cultured, where they are 
able to form monolayers and allow the performance of experiments (Abbott, 2004). Since 
it is difficult to obtain human brain tissue due to ethical constrictions and because the 
tissue received cannot always be regarded as healthy (surgical material or from 
autopsies), a wide range of different animals are used to obtain primary brain endothelial 
cells (Deli et al., 2005; Wilhelm et al., 2011). Although the availability of transgenic 
rodents like mice and rats is appealing (Deli et al., 2005; Wilhelm et al., 2011), because of 
their size the yield of endothelial cells from one brain is relatively small (1-2 
million/brain) (Gumbleton and Audus, 2001; Mensch et al., 2009). Hence models from 
bovine or porcine origin are favoured, having a yield of approximately 200 million 
cells/brain (Mensch et al., 2009). 
However, the cultivation of primary brain endothelial cells can lead to a loss of 
characteristic BBB properties as certain features like transporters and tight junction 
proteins can be down-regulated or subjected to altered expression (Abbott, 2004). To 
overcome these limitations, models that resemble the in vivo situation more closely have 
been developed. Astrocytes are anatomically very close to the endothelial cells in vivo and 
have been used to induce barrier properties by up-regulation of tight junction proteins and 
transporters in vitro (Abbott et al., 2006; Deli et al., 2005). Endothelial cells can be 
cultured either in contact or non-contact co-culture with the astrocytes (Mensch et al., 
2009; Cecchelli et al., 2007). Since astrocytes have been shown to secrete soluble factors 
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to up-regulate barrier characteristics, endothelial cells can also be cultured in astrocyte-
conditioned media, which is taken off of separately cultured astrocytes (Abbott et al., 
2006; Deli et al., 2005). Therefore either rat astrocytes or the C6 glioma cell line are most 
commonly used. Both co-culture and treatment with conditioned media has been shown 
to result in an increase in TEER and a decrease in the permeability of tracer substances 
and polar solutes (Deli et al., 2005). Recently a triple co-culture model has been 
developed, which aims to take the influence of pericytes on the BBB in vivo into account 
(Nakawaga et al., 2009). 
Additionally, an increase of intracellular cAMP, has been shown to lead to tightening of 
the barrier resulting in an increase in TEER and a decreasing permeability of tracer 
substances (Deli et al., 2005; Rubin et al., 1991). Furthermore, when endothelial cells are 
treated with a phosphodiesterase inhibitor, which prevents the quick metabolism of 
cAMP, it is possible to reinforce the effect of cAMP treatment (Deli et al., 2005; Rubin et 
al., 1991). Serum free cultivation and additional treatment with hydrocortisone has also 
lead to increases in TEER (Deli et al., 2005, Hoheisel et al., 1998). 
1.2.2.2.2 Immortalized cell lines 
Immortalized cell lines have been developed, aiming to limit some of the disadvantages 
involved in the cultivation of primary endothelial cells. These disadvantages include the 
labour intensity of isolating the endothelial cells and the problem of batch-to-batch 
reproducibility (Mensch et al., 2009; Bickel, 2005). To generate immortalized cell lines, 
the cells are transformed with viral proteins or genes (Bickel, 2005; Gumbleton and 
Audus, 2001). In general, these cell lines maintain BBB characteristics, but do not form a 
sufficiently tight barrier, that allow the performance of permeability studies (Mensch et 
al., 2009; Gumbleton and Audus, 2001). Well characterized cell lines include the rat 
RBE4 and the human hCMEC/D3 cell line (Cecchelli et al., 2007). 
1.2.3 In silico 
In silico models are computer based models, which offer the advantage of being cheaper, 
less time consuming and high throughput compared to both in vivo and in vitro, earning 
them great popularity especially within the pharmaceutical industry. The difficulty lies in 
the data necessary to generate such models, since experimental protocols differ from 
study to study and not all data is publicly available. Thus, the quality of the model is 
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ultimately determined by the data used to build the model (Mensch et al., 2009).  
Most models concentrate their prediction on the ability of a compound to enter the brain 
by passive diffusion, since this is the route for most drugs across the BBB. However, such 
models do not account for plasma protein binding, metabolism and active influx or efflux 
(Mensch et al., 2009). Apart from the quality and quantity of the data used for the model, 
descriptors and the modelling approach further determine the models quality (Mensch et 
al., 2009). Descriptors are used to define the physicochemical properties of a molecule in 
an attempt to establish a correlation between the molecular structure and its ability to 
cross the BBB. These include molecular weight (MW), lipophilicity (logD7.4), ability to 
form hydrogen bonds and the polar surface area (PSA) (Mensch et al., 2009; Abbott et al., 
2010). In general, a compound is predicted to be able to passively diffuse across the BBB 
if its MW is lower than 450 (Bickel, 2005), its logD is 1-3, it does not form more than 6 
hydrogen bonds and its PSA is less than 80Å
2
 
(Abbott et al., 2010). 
Based on the complex structure and interactions at the BBB it is obvious that generating 
an in silico model to accurately predict BBB permeation in vivo still presents quite a 
challenge. 
1.3 Iron, oxidative stress and neurodegeneration 
1.3.1 Iron 
Iron is essential for all living cells, playing a vital role in processes such as oxygen 
transport, electron transfer, DNA synthesis and enzymatic reactions. Nevertheless, if 
present in excess, iron can be toxic through the generation of free radicals. Iron 
homeostasis in the human body is thus strictly controlled on a cellular and systemic level 
(Camaschella and Strati, 2010; Liu and Hider, 2002). 
In plasma, iron is bound to the glycoprotein transferrin and transferrin bound iron is 
transported into the cells via the transferrin receptor (Hentze et al., 2010). Iron delivery to 
the CNS takes place via the transferrin route or via non-transferrin-bound iron pathways 
involving divalent metal transporter 1 or lactoferrin and ferritin and their receptors (Li et 
al., 2010).  
In neurons iron is stored in the lysome or bound to sequestration proteins like ferritin or 
neuromelanin (Li et al., 2010) and iron homeostasis is controlled through 
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posttranscriptional regulation via the iron regulatory protein (IRP)/ iron responsive 
element (IRE) system (Gille and Reichmann, 2011). According to intracellular iron levels 
the IRP undergoes structural changes which result in a change of binding affinity for the 
IRE located in either the 3' or 5' untranslated region of the target protein's mRNA. The 
expression of proteins involved in iron uptake, storage, transport and utilization are 
therefore controlled by intracellular iron concentrations (Altamura and Muckenthaler, 
2009). For example, iron depletion induces IRP binding in the 3' untranslated region of 
the transferrin receptor mRNA, which stabilizes it and increases translation subsequently 
promoting more iron to be transported into the cells. In contrast, iron repletion induces 
binding in the 5' untranslated region of transferrin receptor mRNA, which inhibits its 
translation (Li et al., 2010; Hentze et al., 2010).  
In the brain iron is required for both neurodevelopment and normal function (Horowitz 
and Greenamyre, 2010), since iron is a cofactor in enzymes involved in the synthesis and 
metabolism of neurotransmitters as well as being involved in the process of  axon 
myelination (Altamura and Muckenthaler, 2009; Horowitz and Greenamyre, 2010). 
1.3.2 Oxidative stress 
Oxidative stress is characterized as an imbalance between the production of free radicals 
and the antioxidant defence system of the cell (Hider et al., 2011). A free radical is 
defined as a molecule or atom with an unpaired electron, rendering it unstable and 
reactive (Higgins et al., 2010; Jomova et al., 2010). Under physiological conditions free 
radicals are by-products of intracellular oxygen metabolism, being generated during the 
oxidative phosphorylation in mitochondria (Higgins et al, 2010). The most important are 
derived from oxygen (ROS, reactive oxygen species) including the superoxide (O2
·-
), 
hydroxyl (OH
·
) and nitric oxide (NO
·
) radical. However, the non-radicals hydrogen 
peroxide (H2O2) and peroxynitrite (ONOO
-
) also contribute to the cells redox state (Hider 
et al., 2011). As a defence against free radicals the body has various systems that include 
superoxide dismutase, catalase, glutathione and vitamin E (Higgins et al., 2010; Hider et 
al., 2011). 
Iron is bound to sequestration proteins and safely liganded in enzymes considering that 
free or poorly liganded Fe(II) can participate in the Fenton reaction, which leads to the 
generation of the hydroxyl radical (Jamova et al., 2010; Kell, 2010).  
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Fe
2+
 + H2O2 → Fe
3+ 
+ OH
-
 + OH
. 
Scheme 1: Fenton reaction 
 
The hydroxyl radical, as well as other free radicals, is able to react with biomolecules 
such as DNA, RNA, lipids and proteins causing oxidative modifications in the molecules. 
These modified biomolecules can accumulate intracellularly, which can further lead to 
dysfunction and through the activation of various signalling pathways can result in cell 
death (Hider et al., 2011; Salvador et al., 2010). 
1.3.3 Neurodegeneration and oxidative stress 
Neurodegenerative diseases involve the progressive death of neurons, usually affecting 
disease specific types of neurons (Gaeta and Hider, 2005). The primary risk factor for 
neurodegenerative diseases is age, which is linked to increased oxidative stress, and 
oxidative stress has been shown to play a key role in the pathology of various 
neurodegenerative diseases (Molina-Holgado et al., 2007). Common features are found in 
diseases such as Alzheimer's and Parkinson's disease, that include the aggregation of 
modified proteins, the accumulation of which is neurotoxic, high levels of metals and 
oxidative damage. The brain and its sensitive neurons are at particular risk of oxidative 
damage, since the brain accounts for about 20% of total body oxygen consumption. 
Additionally, relatively low levels of antioxidants are present and the brain has a tendency 
to accumulate metals with age, which might provide the link between oxidative stress and 
protein aggregation (Molina-Holgado et al., 2007).  
1.3.3.1 Alzheimer's disease 
Alzheimer's disease (AD) is the most common neurodegenerative disease, affecting about 
18 million people worldwide and clinically manifests with cognitive impairment, memory 
loss and dementia (Kenche and Barnham, 2011). Its characteristic pathological hallmarks 
are the presence of intracellular neurofibrillary tangles consisting of the hyper-
phosphorylated microtubule-associated protein tau, and the extracellular deposition of 
senile plaques consisting of amyloid β (Aβ) (Ballard et al., 2011).  
Out of the different isoforms of Aβ (39-42 amino acids in length) that originate from 
proteolytic cleavage of the amyloid precursor protein APP, Aβ(1-42) is found to be 
particularly toxic to cells due to its fibrillogenic activity (Hider et al., 2011).  Aβ(1-42) 
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can bind Zn(II), Cu(II) and Fe(III) via 3 histidine and a methionine residue in the peptide 
(Altamura and Muckenthaler, 2009; Molina-Holgado et al., 2007), thus mediating the 
formation of  free radicals as a consequence of metal binding (Tabner et al., 2005; Hider 
et al., 2011). Iron is found to accumulate in the same regions as Aβ extracellularly and 
intracellularly in neurons containing neurofibrillary tangles (Salvador et al., 2010; 
Horowitz and Greenamyre, 2010). Iron concentrations in the brain are 3-5 times higher 
when compared to age matched controls (Molina-Holgado et al., 2007) and both Aß 
aggregation and tau hyperphosphorylation have been shown to be inducible by iron 
(Horowitz and Greenamyre, 2010). Additionally, Aβ is reported to participate in a vicious 
cycle, where oxidative stress induces Aβ production, and the oxidative stress associated 
with metal binding and Aβ aggregation in turn enhances Aβ production yet again 
(Molina-Holgado et al.,2007; Salvador et al., 2010). 
1.3.3.2 Parkinson's disease 
Parkinson's disease (PD) is characterized by the selective degeneration of dopaminergic 
neurons in the substantia nigra pars compacta, which leads to a significant loss of 
dopamine in the striatum, causing symptoms like tremor, bradykinesia, dyskinesia and 
rigidity (Schapira et al., 2006; Altamura and Muckenthaler, 2009). Additionally, 
intracellular inclusions of protein aggregates (Lewy Bodies) are found, which mainly 
consist of α-synuclein. Iron tends to accumulate in the Lewy Bodies, where it has been 
shown to be able to promote and induce α-synuclein aggregation (Altamura and 
Muckenthaler, 2009; Snyder and Connor, 2010). Through the interaction with α-synuclein 
iron can mediate the generation of free radicals causing oxidative damage as a 
consequence. Oxidative damage is found in PD post-mortem brains affecting DNA, lipids 
and proteins (Hider et al., 2011).  
Furthermore, ferritin levels in the PD brain are lower and ferritin is highly loaded with 
iron compared to controls (Altamura and Muckenthaler, 2009). As a consequence of 
increased iron levels, neuromelanin is oversaturated with iron, thus the loosely bound iron 
retains its redox activity and can generate the formation of free radicals (Horowitz and 
Greenamyre, 2010; Gaeta and Hider, 2005). Moreover, mitochondria dysfunction and 
reduced levels of antioxidants like glutathione are also found in PD post-mortem brains 
(Molina-Holgado et al., 2007). 
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1.3.3.3 Friedreich's Ataxia 
Friedreich's Ataxia is an autosomal recessive degenerative disease that involves the 
expansion of a trinucleotide repeat in the first intron of the gene encoding for the 
mitochondrial iron chaperone protein fraxitin (Boddaert et al., 2007). This leads to a 
decreased expression of fraxitin and therefore an increase in mitochondrial iron levels. 
Subsequently, the high iron levels result in iron-mediated oxidative damage affecting the 
sensory neurons, the heart and the endocrine glands (Whitnall and Richardson, 2006). 
1.3.4 Iron chelation as a therapeutic strategy 
It is still a matter of scientific debate whether oxidative stress associated with high levels 
of metals like copper, zinc and iron in the brain is the primary cause or a result of the 
progression of neurodegenerative diseases like AD and PD. Nevertheless, it provides a 
promising new target for the treatment of these diseases (Gaeta and Hider, 2005). 
There are several factors that need to be taken into consideration when designing a 
clinical useful chelator. First of all, metal selectivity is a key factor, especially in reducing 
side effects of chelation therapy. In the case of AD, copper, iron and zinc have been 
shown to contribute to the disease, whereas in PD iron is the main identified metal 
involved (Hider et al., 2011). 
Iron chelators can be structurally classified according to the number of donor atoms 
interacting with the iron ion. When six donor atoms are present in one single molecule, it 
is referred to as hexadentate, when 2, 3 or more coordinating donor atoms are present in 
one molecule, the chelator is named bidentate, tridentate or multidenate respectively (Liu 
and Hider, 2002). 
 
 
 
Figure 4: Schematic representation of iron-ligand complexes  
(from Gaeta and Hider, 2005) 
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Chelators can be designed to be selective for either Fe(II) or Fe(III). Selective Fe(II) 
chelators use nitrogen atoms as donor atoms, whereas Fe(III) selective chelators use 
oxygen atoms. There are major advantages for the use of Fe(III) selective chelators, since 
Fe(II) chelators also have an affinity to bind bivalent metals such as Cu(II) and Zn(II). 
Contrary to copper and zinc, tribasic metals like aluminium(III) and gallium(III) are not 
essential for living cells, rendering Fe(III) selective chelators the therapeutic strategy for 
iron chelation (Hider et al., 2008). Furthermore, Fe(III) selective chelators can also bind 
Fe(II) under aerobic conditions and induce autoxidation to Fe(III), which enables them to 
bind iron under most physiological conditions (Hider et al., 2008). 
For the successful application of iron chelators in the treatment of neurodegenerative 
diseases, it is necessary for the chelator to be able to scavenge the redox active iron from 
the brain. Additionally beneficial would be the ability to scavenge the labile iron from its 
binding site as well to prevent mediated oxidative damage (Hider et al., 2008). Preferably 
a non-charged complex of the chelator with iron should be formed to facilitate efflux 
through passive diffusion, thereby removing the iron from the brain (Hider et al., 2011). 
To achieve this, a chelator must first of all have the ability to cross the blood-brain barrier 
(BBB). Therefore it is suggested that the size is limited to less than 400 Da, which 
eliminates hexadentate chelators from consideration. Lipophilic drugs tend to be able to 
cross the BBB better than hydrophilic drugs, but liver first pass effect as a consequence of 
increased lipophilicity of the chelator must not be neglected (Hider et al., 2011). 
A problem associated with iron chelation therapy is toxicity due to inhibition of iron 
containing enzymes. Iron chelators have been shown not to directly inhibit haem 
containing enzymes since the porphyrin bound iron is inaccessible, nevertheless non-
haem containing enzymes such as lipoxygenase, the aromatic hydroxylase family and 
ribonucleotide reductase can be affected (Hider et al., 2011). For the potential application 
of iron chelators for the treatment of neurodegenerative diseases, possible interactions 
with the enzymes involved in the synthesis and metabolism of dopamine and serotonin 
have to be taken into careful consideration as well. By modifying the physicochemical 
properties of the chelating agent it is possible to limit such interactions (Hider et al., 
2011).  
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1.3.4.1 Hydroxypyridinones 
Hydroxypyridinones (HPO) are bidentate iron chelators that form a stable and non-
charged 3:1 complex with Fe(III). Out of this class, 3-hydroxypyridin-4-ones have the 
highest affinity for Fe(III) (Liu and Hider, 2002) and the complexes with Fe(III) have an 
extremely low redox potential (Hider et al., 2011). The most prominent 3-hydroxypyridin-
4-one is deferiprone (Ferriprox
®
), which is the only orally active iron chelator available. 
Deferiprone is successfully used for the treatment of iron overload associated with the 
genetic haematological disease β-Thalassaemia (Liu and Hider, 2002). Due to the fact that 
deferiprone forms neutral complexes with iron and its small size, it is able to permeate 
membranes by passive diffusion and eliminate iron from various tissues including the 
heart (Hider et al., 2011).  
 
 
 
 
 
Moreover, its ability to cross the BBB has been shown and deferiprone has been 
introduced as a treatment for patients suffering from Friedreich's Ataxia (Hider at al., 
2011). In addition, the application of deferiprone in other neurodegenerative diseases 
associated with iron-mediated oxidative stress like Alzheimer's and Parkinson's disease 
has been suggested and deferiprone is currently under investigation in a clinical trial for 
the treatment of Parkinson's disease. 
Even though deferiprone has a moderate ability to cross the BBB, the search for more 
efficient chelators continues. Therefore a series of fluorinated 3-hydroxypyridin-4-ones 
has been designed and synthesized to enhance BBB permeability without increasing liver 
first pass effect (Ma and Hider, 2010; Hider et al., 2011). Some of these compounds have 
been used in the following study. 
Formula 1: deferiprone 
N
O
OH
CH
3
CH
3
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1.4 Aims and objectives 
Primary porcine brain endothelial cells (PBEC) were used as an in vitro model to assess 
the blood-brain barrier permeability of six 3-hydroxypyridin-4ones (HPO). For the 
selected HPOs, in vivo data was already available. Thus, the aim was to investigate 
whether it is possible to correlate in vivo and in vitro data, which would allow predictions 
of in vivo blood-brain barrier permeability to be made from in vitro data.  
The objectives were defined as follows: 
 assessing toxicity of the 3-hydroxypyridin-4ones on PBECs 
 assessing the effect of different culture conditions on the quality of the PBEC 
monolayer 
 assessing blood-brain barrier permeability of the 3-hydroxypyridin-4ones in vitro 
 correlating in vivo and in vitro data 
21 
 
2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals 
All chemicals were obtained from Sigma Aldrich unless stated otherwise. Bovine plasma 
derived serum (BPDS) was purchased from FirstLink UK, RO-20-1724 was purchased 
from Calbiochem and Dulbeco's modified eagle medium (DMEM) was obtained from 
Invitrogen. The Thermo Scientific Pierce BCA Protein Assay Kit was purchased from 
Thermo Scientific. Acetonitrile (HPLC gradient grade) and 1-heptane sulfonic acid were 
obtained from Fisher Scientific UK. The 3-hydroxypyridin-4ones (HPOs) used in this 
study were synthesized by Dr. Yong Min Ma. Structures and physicochemical properties 
are shown in Table 1.  
2.1.2 Cells 
Primary porcine brain endothelial cells (PBEC) were obtained from Ana Georgian and 
Siti Yusof using the isolation protocol described in 2.2.1.1. Primary astrocytes were 
obtained from Siti Yusof and C6 glioblastoma were received as gift to the King's College 
London Blood-Brain Barrier group from the Babraham Institute, Cambridge. 
2.1.3 Analytical apparatus 
A Labsystems Multiskan Ascent microplate reader was used to measure absorbance for 
the MTT and BCA assay. To measure fluorescence for the analysis of sodium fluorescein 
concentrations, a FlexStation microplate reader was used. Transendothelial electrical 
resistance (TEER) was measured using an STX100 probe and an EVOM volt-ohmeter. 
HPLC was performed on a Waters system consisting of a 717plus Autosampler, a 
2996 Photodiode Array Detector, a 600s Controller and a 626 Pump. 
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Table 1: Structure, molecular weight (MW) and logD7.4 of the HPOs used in this study 
Compound Structure MW logD7.4 
CP20 
 
139 -0.77 
YMF 8 
 
157 -0.75 
YMF 16 
 
157 -0.95 
YMF 24 
 
171 -0.05 
YMF 25 
 
171 -0.54 
YMF 29 
 
186 -1.00 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Cerebral microvessel endothelial cell isolation 
Porcine brain endothelial cells (PBEC) were isolated based on the methods of Rubin et al. 
(1991), and Skinner et al. (2009). Porcine brains were obtained from a slaughterhouse and 
transported in L-15 medium containing 100U.mL
-1 penicillin and 100μg.mL-1 
streptomycin. The brain hemispheres were washed in phosphate-buffered saline (PBS), 
cleared of meninges and stored in ice cold PBS. After the removal of the white matter, the 
brain tissue was sliced into small pieces and homogenized in MEM/HEPES media 
containing 10% (v/v) fetal calf serum (FCS). Subsequently the homogenate was filtered 
through a 150μm nylon mesh, followed by filtration through a 60μm nylon mesh. The 
brain tissue on both meshes was then digested using M199 medium containing 10% (v/v) 
FCS, 100U.mL
-1
 penicillin, 100μg.mL-1
 
streptomycin, 210 U.mL
-1
 collagenase, 
114 U.mL
-1
 DNAse I and 91 U.mL
-1
 trypsin-EDTA for 1 hour at 37°C. The digestive mix 
was washed off the mesh with MEM/HEPES and centrifuged for 10minutes at 1000 x g. 
The pellet, formed by the cerebral microvessels, was then resuspended in FCS containing 
10% (v/v) DMSO. One mL aliquots were frozen at -80°C for 24h and then moved into 
liquid nitrogen, where the cerebral microvessels were stored for further use. Isolations 
were performed by Ana Georgian and Siti Yusof. 
2.2.1.2 Defrosting PBECs 
Two T-75 flasks were each coated with 4ml of rat tail collagen (100μg.mL-1), at room 
temperature, for a minimum of 2 hours. The flasks were washed twice with 4mL HBSS 
and then coated with 4mL fibronectin (7.5μg.mL-1) each, at room temperature, for a 
minimum of 2 hours. The coating was removed and the flasks were washed twice with 
4ml HBSS each. Afterwards, PBEC media (DMEM containing 10% (v/v) BPDS, 
100U.mL
-1
 penicillin, 100μg.mL-1 streptomycin, 2mM L-glutamine and 125μg.mL-1 
heparin) was prepared and 4μg.mL-1 puromycin was added to the PBEC media before 
sterile filtration (pore size 0.2μm).  
Puromycin is a P-gp substrate used to purify endothelial cell cultures. Since endothelial 
cells highly express P-gp, puromycin is actively effluxed out of the endothelial cells, 
hence concentrations otherwise toxic can be used. In contrast to endothelial cells, 
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contaminating cell types (for example fibroblasts or pericytes) lack P-gp expression and 
will not survive the puromycin treatment (Perrière et al. 2005). 
The freshly prepared PBEC media was warmed in a water bath and then used to 
resuspend PBECs that were stored in liquid nitrogen. Subsequently, 10mL of cell 
suspension was placed into each of the pre-coated flasks. PBECs were kept in an 
incubator at 37°C and 5% CO2. The media was replaced with freshly prepared media 
without puromycin after 3 days. 
2.2.1.3 Passaging PBECs 
PBECs were passaged when growth reached 30% confluence and small clusters of cells 
were visible which was closely monitored using an inverted light microscope. PBECs 
reached that state after 3-6 days in culture. 
For passaging, each T-75 flask of cells was washed twice with 10mL HBSS (with 
phenolred, without Ca
2+
 and Mg
2+
) before 2.5mL of trypsin-EDTA was added and the 
flasks were placed into the incubator at 37°C. After 8-10min in the incubator, the number 
of cells that had detached from the bottom of the flask was determined using the inverted 
light microscope, while gently tapping the flask. If necessary, the flasks were placed into 
the incubator at 37°C for further 5min. When 80% of the cells had detached from the 
bottom of the flask, 8mL of freshly prepared warm PBEC media was added to each flask 
and the cells were pooled into a universal tube for centrifugation. After PBECs were 
centrifuged at 1500 rpm for 5 min, the supernatant was removed and the cell pellet was 
 
Figure 5: Confluent PBEC 
monolayer (from Bobilya et 
al., 1995) 
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resuspended in 1mL PBEC media (DMEM containing 10% (v/v) BPDS, 100U.mL
-1 
penicillin, 100μg.mL-1 streptomycin, 2mM L-glutamine and 125μg.mL-1 heparine). 
From the cell suspension 10μL was removed to count cells using a haemocytometer. 
PBECs were then resuspended in the correct amount of media and seeded into either a 
96 well plate or into the Transwell® system. 
For seeding PBECs into a 96 well plate, the plate was pre-coated with 200μL of rat tail 
collagen (100μg.mL-1) per well using the protocol described for coating culture flasks. 
PBECs were seeded at a density of 0.3x10
^5
 cells per well. 
For seeding PBECs into Transwell®  filter inserts (polycarbonate filters, pore size 0.4μm, 
area 1.12cm
2
), Transwell® inserts were pre-coated with 500μL of rat tail collagen 
(100μg.mL-1) followed by 500μL of fibronectin (7.5μg.mL-1) as described for coating 
culture flasks. PBECs were seeded at a density of 1x10
^5
 cells per filter insert.  
For non-contact co-culture with C6 glioblastoma, PBECs were seeded into Transwell® 
inserts, which were placed above confluent C6 glioblastoma. 
2.2.1.4 Primary astrocytes 
Primary astrocytes were defrosted similarly to the PBECs. Two T-75 flasks were pre-
coated with 4mL poly L-lysine (10μg.mL-1) each, for 30min at 37°C. Poly L-lysine 
coating was then removed and the flasks were left to dry at room temperature. Primary 
astrocytes, that were stored in liquid nitrogen, were resuspended in 10mL astrocyte media 
(DMEM (with high glucose and pyruvate) containing 10% (v/v) FCS and 100U.mL
-1
 
penicillin) before being placed into the pre-coated, dry flasks. Astrocytes were kept in an 
incubator at 37°C and 5% CO2. 
2.2.1.4.1 Collection of astrocyte-conditioned media 
Astrocytes grew confluent after 7-10 days in culture. When confluence was reached, the 
conditioned media was taken off every 2 days and replaced with freshly prepared 
astrocyte media. Astrocyte-conditioned media (ACM) was collected from primary 
astrocytes of up to 30 days in culture and conditioned media was either used immediately 
or stored at -20°C for further use. 
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2.2.1.5 C6 glioblastoma 
C6 glioblastoma cells (passage 130) were defrosted as described for the primary 
astrocytes, but without any pre-coating of the culture flasks. C6 glioblastoma were 
passaged into 12 well plates as described for PBECs using trypsin-EDTA and astrocyte 
media (DMEM (with high glucose and pyruvate) containing 10% (v/v) FCS and 
100U.mL
-1
 penicillin). C6 glioblastoma cells were seeded at a density of 1x10
^5
 per well 
and grew confluent within 3 days in culture (37°C and 5% CO2). 
2.2.2 Assessing cell viability 
2.2.2.1 Cytotoxicity assay 
To assess the cytotoxicity of the HPOs on cultured PBECs, the MTT assay was used. This 
is a quantitative, calorimetric assay to determine cell viability. The quantification is based 
on the reduction of the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) to a blue water insoluble formazan salt by the mitochondrial 
enzyme succinate dehydrogenase in living cells. The blue formazan salt can be dissolved 
in an organic solvent and the absorbance measured is directly proportional to the amount 
of living cells in the sample (Mosmann, 1983; Denizot and Lang, 1986). 
The MTT assay was conducted in 96 well plates on 100% confluent PBECs. Solutions of 
800μM HPO in assay buffer (HBSS, 25mM HEPES, 0.1% (v/v) BSA, pH 7.4) were 
prepared and warmed at 37°C. The media was removed from the PBECs and the cells 
were incubated with 200μL of the HPO-solutions per well for 2 hours at 37°C. HPO-
solutions were removed and cells were washed twice with HBSS (200μL per well). Then, 
100μL MTT-solution (1mg.mL-1 MTT in DMEM (without phenolred)) was added to each 
well and incubated at 37°C and 5% CO2 for 4 hours. To remove the well contents the 
plate was turned over and blotted, leaving just the blue crystals (formazan salt) that were 
formed on the bottom of the wells. The crystals were dissolved in 100μL propan-2-ol and 
absorbance at 540nm was measured on a Labsystems Multiskan Ascent microplate reader. 
2.2.2.2 BCA protein assay 
The BCA Protein Assay is a quantitative colorimetric assay to determine the protein 
concentration of a sample based on the reduction of Cu
2+
 to Cu
1+
 by peptides in an 
alkaline medium. The Cu
1+ 
ion interacts with 2-bicinchoninic acid (BCA), forming a 
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purple water soluble complex with a measurable absorbance at 562nm. The absorbance 
measured correlates with the protein concentration in the sample. To calculate protein 
concentrations, a standard curve of bovine serum albumin (BSA) in known concentrations 
is used (Smith et al., 1985). 
The BCA protein assay was conducted in 96 well plates on 100% confluent PBECs. 
HPO-solutions in assay buffer (HBSS, 25mM HEPES, 0.1% (v/v) BSA, pH 7.4) were 
prepared at a concentration of 800μM and warmed at 37°C.  After the removal of the 
media, the PBECs were incubated with 200μL of the HPO-solution per well for 2 hours at 
37°C. The solutions were then removed and 200μL Triton X (1% (v/v) in distilled water) 
was added to each well to lyse the cells for 45 minutes at 37°C. An aliquot of 100μL cell 
lysate was transferred to a new 96 well plate and incubated with 100μL BCA working 
reagent (solution A containing sodium carbonate, sodium bicarbonate, bicinchoninic acid 
and sodium tatrate in 0.2N sodium hydroxide and solution B containing 4% cupric 
sulphate; A:B = 50:1) for 30 minutes at 37°C. Standards of 100μL BSA in different 
concentrations (0, 10, 15, 20, 25 and 30μg.mL-1) were incubated with the BCA working 
reagent alongside the samples as described above. The absorbance at 562nm was 
measured using a Labsystems Multiskan Ascent microplate reader and protein 
concentrations were calculated using the BSA standard curve produced by Ascent 
Software. 
2.2.2.3 Calculating overall cell viability 
To get a correct value for cell viability, the MTT assay was conducted on half the wells, 
for the other half a BCA assay was done. Overall cell viability was calculated and 
expressed as absorbance measured per μg protein. PBECs not treated with HPO served as 
a control to evaluate the results. 
2.2.3 Permeability assay 
To study the transport of the HPOs across the blood-brain barrier in vitro, a Transwell® 
system was used. PBECs were grown in Transwell® inserts with polycarbonate filters 
(pore size 0.4μm; area 1.12cm2) suspended above 12 well plates. In this experimental set 
up, the donor chamber (apical chamber) mimics the apical side of the endothelium 
(blood) whereas the receiver chamber (basolateral chamber) mimics the basolateral side 
of the endothelium (brain) as shown in Figure 6. 
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2.2.3.1 Culture conditions 
PBECs in Transwell® inserts were grown under 3 different culture conditions. 
 PBECs grown in monoculture 
 PBECs grown in monoculture and treated with 50% astrocyte-conditioned media 
(ACM) on the basolateral chamber 
 PBECs grown in non-contact co-culture with C6 glioblastoma cells, with C6 
glioblastoma grown on the bottom of the 12 well plates underneath the filter insert 
(Figure 7) 
2.2.3.2 Enhancing barrier properties 
PBECs were passaged into Transwell® inserts and grew confluent within 3 days. Since 
polycarbonate filters are opaque, PBECs seeded on polyethylene filter inserts (see-
through) served as a reference to monitor the growth. After confluence was reached, the 
media was replaced with serum free PBEC media (DMEM, 100U.mL
-1
 penicillin, 
 
Figure 7: Schematic representation of a Transwell® 
insert with PBECs grown in non-contact co-culture 
with C6 glioblastoma 
Figure 6: Schematic representation of a Transwell® insert used 
for the in vitro permeability assay 
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100μg.mL-1 streptomycin, 2mmol.L-1
 
L-glutamine and 125μg.mL-1 heparin) that was 
additionally supplemented with 550nM hydrocortisone. Furthermore, PBECs were treated 
with 250μM 8-4-chlorophenylthio-cAMP (CTP-cAMP) and 17.5μM of phosphodiesterase 
inhibitor RO-20-1724 (RO). 
2.2.3.2.1 Treatment for the different culture conditions 
PBECs in monoculture and PBECs grown in non-contact co-culture with C6 glioblastoma 
received treatment with serum free media, hydrocortisone, CPT-cAMP and RO. 
PBECs grown with astrocyte-conditioned media (ACM) were treated with serum free 
media, hydrocortisone, CPT-cAMP and RO as described above. Additionally, ACM was 
supplemented into the basolateral chamber at a concentration of 50% using the ACM 
harvested from primary astrocytes. 
2.2.3.3 Determining the quality of the barrier 
2.2.3.3.1 Measurement of TEER 
After 24 hours of treatment with serum free media, hydrocortisone, CPT-cAMP and RO, 
transendothelial electrical resistance (TEER) was measured using an STX100 probe and 
an EVOM volt-ohmeter.  
 
TEER represents the movement of small ions via the paracellular pathway and depends 
on the amount and complexity of tight junctions formed between the endothelial cells. 
Therefore TEER measurements were carried out before the permeability assay to 
determine the quality of the barrier. 
Figure 8: Schematic representation of the TEER 
measurement with copstick electrodes (from 
Cardoso et al., 2010) 
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Final electrical resistance of the PBEC monolayer was calculated by subtracting the value 
of a collagen coated Transwell® insert (no cells) from the resistance measured for the 
insert with PBECs and multiplied by the area of the Transwell® insert. TEER is 
expressed in Ω.cm2. 
 
 
 
 
 
 
2.2.3.3.2 Paracellular marker 
To further asses the quality of the endothelial cell barrier, sodium fluorescein was used as 
a paracellular marker during the permeability assay. Sodium fluorescein is known not to 
penetrate into endothelial cells, so when added to the apical chamber its only route of 
transfer to the basolateral chamber is via the paracellular route. Therefore, measuring the 
permeability of sodium fluorescein to the basolateral chamber is indicative of the 
tightness of the junctions formed between the PBECs. 
2.2.3.4 Experiment protocol 
The wells of 12 well plates were filled with 1.5mL assay buffer (HBSS, 25mM HEPES, 
0.1% (v/v) BSA, pH 7.4) and warmed to 37°C. Solutions of 800μM HPO in permeability 
buffer (assay buffer containing sodium fluorescein (10μg.mL-1)) were prepared and also 
warmed at 37°C. The media was removed from both apical and basolateral chamber of 
the PBEC cultures and the Transwell® inserts were placed into the 12 well plates that 
already contained the 1.5mL of warm assay buffer (basolateral chamber). To the apical 
chamber of the inserts, 500μL HPO-solution in permeability buffer was added and the 
plates were shaken at 200 rpm in an orbital shaker at 37°C. After 20 minutes, the inserts 
were moved into a new 12 well plate to prevent any transport into the basolateral chamber 
while samples were taken from both the apical and the basolateral chamber. 
To determine the concentration of the paracellular marker sodium fluorescein, 100μL 
Formula 2: sodium fluorescein 
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samples were taken from the apical and basolateral chamber and pipetted into a 96 well 
plate. The 96 well plate also contained assay buffer (0% sodium fluorescein) and 
permeability buffer in different concentrations (100%, 90%, 75%, 25%, 12.5%, 6.25%, 
3.125%, 1.56%, 0.78%, 0.39% sodium fluorescein) to establish a standard curve. 
Fluorescence was measured at an excitation wavelength of 485nm and an emission 
wavelength of 530nm, and sodium fluorescein concentrations in the samples were 
calculated according to the standard curve. 
To determine the concentration of HPO transferred through the cell monolayer, 300μL 
samples were taken from the apical chamber and 1.3mL samples were taken from the 
basolateral chamber for further analysis with HPLC. 
2.2.3.5 Correcting HPO transfer 
HPO concentrations in the basolateral chamber were determined at the end of the 
permeability assay and then corrected for paracellular transfer. Thus, data acquired for 
sodium fluorescein transfer was used to determine the proportion of HPO transfer via the 
paracellular route and subtracted from the overall HPO transfer. 
2.2.3.6 Calculating intracellular accumulation 
Intracellular accumulation was defined and calculated as the HPO concentration not 
recovered after summing the concentrations determined for both apical and basolateral 
chamber at the end of the permeability assay, compared to the initial HPO concentration 
in the apical chamber. 
2.2.4 HPLC 
To determine HPO concentrations in the samples taken from the permeability assay, high 
performance liquid chromatography (HPLC) was used.  
HPLC was performed using a reversed-phase polymer column (PLRP-S 300Å, 
15 x 0.46 cm, internal diameter 8μm). A gradient ion-pair method (Liu et al., 1999) was 
applied, using 5mM 1-heptanesulfonic acid sodium salt (adjusted to pH 2 using HCl) as 
the ion-pair buffer. A gradient of 2-35% acetonitrile over 20 minutes was followed by a 
post-run of 5 minutes to restore initial conditions (2% acetonitrile and 98% buffer). The 
flow rate was 1mL/min and HPOs were monitored at 280nm. 100μL of the samples were 
injected as quadruples. 
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Standard curves of all HPOs were produced prior to the permeability assay, using 
different concentrations of the HPOs (1000, 750, 500, 200, 100, 50, 25, 10, 5μM) in 
HPLC-water. Injections of 100μL were done in quadruples and the area under the curve 
(AUC) was plotted against the concentration to establish a standard curve. These standard 
curves were used to calculate the concentration of the HPOs in the samples from the 
permeability assay. 
Chromatograms were produced and analysed by Millennium Software.  
2.2.5 Statistical analysis 
Statistical analysis of the experimental data was conducted with Graph Prism 5 using one 
way ANOVA and Tukey’s multiple comparison test as the post test. 
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3 RESULTS 
3.1 Viability 
In order to accurately compare the in vitro and in vivo data, the concentration used to 
perform the in vivo experiments (800μM) was aimed to be used in the in vitro assays as 
well. Hence, it was investigated whether this concentration affected PBEC viability 
before the permeability assays were performed. The viability was assessed using the MTT 
and the BCA assay.  
3.1.1 CP20  
Since CP20 (deferiprone) served as the reference HPO is this study, its effect on PBECs 
was investigated first. PBECs were exposed to CP20 for 2 hours at a concentration of 
100μM, 400μM and 800μM. PBECs not exposed to CP20 were used as a control to 
evaluate the results.  
 
 
Figure 10: Absorbance measured at 540nm, 
after the MTT assay was conducted on PBECs 
incubated with CP20 for 2 hours. 
Data is represented as mean ± SEM (n=4). 
Figure 9: Protein content per well in μg, 
determined after performing the BCA assay on 
PBECs incubated with CP20 for 2 hours. 
Data is represented as mean ± SEM (n=4). 
. 
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Overall viability was calculated using data from the MTT and the BCA assay as described 
in methods and materials (2.2.2.3) and expressed as absorbance measured per μg protein. 
No statistically significant difference was found between the viability of PBECs in the 
control group compared to PBECs that were exposed to 100μM and 400μM CP20 after 
the 2 hour incubation. Furthermore, PBECs remained viable after 2 hour incubation with 
800μM CP20 compared to control (Figure 11). 
3.1.2 HPO viability  
CP20 could be shown not to be toxic to PBECs at the concentration of 800μM over 
2 hours, hence the effect of the other HPOs on PBEC viability was assessed using the 
same concentration. The permeability assays were planned to be performed for 20min, 
therefore PBECs were incubated with 800μM of HPO solution for 20min. The effect of 
the exposure to 800μM HPO solution for 2 hours was determined as well. 
 
Figure 11: PBEC overall viability after incubation with 
CP20 for 2 hours, expressed in absorbance per μg protein. 
Data is represented as mean ± SEM (n=4). 
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3.1.2.1 Viability after 20min incubation 
 
 
 
 
Figure 13: Absorbance measured at 540nm, 
after the MTT assay was conducted on PBECs 
incubated with 800μM HPO for 20min. 
Data is represented as mean ± SEM (n=3).  
Figure 12: Protein content per well in μg, 
determined after performing the BCA assay on 
PBECs incubated with 800μM HPO for 20min. 
Data is represented as mean ± SEM (n=3).  
Figure 14: PBEC overall viability, expressed in 
absorbance per μg protein, after incubation with 800μM 
HPO for 20min. 
Data is represented as mean ± SEM (n=3). 
Difference from control: ** p< 0.01 
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Only compounds YMF 16 and YMF 24 reduced PBEC viability after 20min exposure to 
800μM (Figure 14) with 75 ± 2.58% of PBECs remaining viable after incubation with 
YMF 16 and 71.61 ± 4.86% in the case of PBECs incubated with YMF 24, compared to 
control. For compound YMF 8, YMF 25 and YMF 29 no toxic effect on the PBECs was 
found after 20min incubation. 
3.1.2.2 Viability after 2 hour incubation 
Following the assessment of PBEC viability for an incubation time of 20min with 800μM 
HPO solution, the effect of a longer exposure was studied using 2 hours as the end time 
point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Absorbance measured at 540nm, 
after the MTT assay was conducted on PBECs 
incubated with 800μM HPO for 2 hours. 
Data is represented as mean ± SEM (n=3). 
 
Figure 16: Protein content per well in μg, 
determined after performing the BCA assay 
on PBECs incubated with 800μM HPO for 
2 hours. 
Data is represented as mean ± SEM (n=3). 
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After a 2 hour exposure of PBECs to 800μM HPO solution, compound YMF 16 and 
YMF 24 reduced viability as has been observed after incubation for 20min. Moreover, 
after the exposure time of 2 hours also compound YMF 8 showed an effect on the 
viability of the PBECs, whereas it had not been found to affect viability after 20min. 
However, 82.79 ± 3.89% of PBECs treated with YMF 8 remained viable when compared 
to control cells. In the case of PBECs incubated with compounds YMF 16 and YMF 24, 
compared to control, 81.14 ± 2.79% and 76.31± 2.20% of cells remained viable 
respectively. Compound YMF 25 had no toxic effect on PBECs even after 2 hours of 
exposure. 
3.2 CP20 time-dependent transport 
The time-dependent transport across the PBEC monolayer was determined for CP20, the 
reference HPO in this study. In the in vivo experiments 20min was used as the end time 
point for the in situ brain perfusion. Hence it was necessary to evaluate whether CP20 
transport during the 20min in vitro assay was sufficient in order to enable quantitative 
analysis with HPLC. 
 
Figure 17: Overall viability, expressed in absorbance per 
μg protein for PBECs incubated with 800μM HPO for     
2 hours. 
Data is represented as mean ± SEM (n=3). 
Difference from control: ** p< 0.01/ *** p< 0.001 
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Therefore, Transwell® inserts were moved to a new basolateral chamber filled with assay 
buffer at different time points and CP20 concentrations were determined for each of these 
time points. 
Three different experimental conditions were applied. For condition 1 Transwell® inserts 
were moved at 5, 10, 20, 30, 40 and 60min. For condition 2 the Transwell® inserts were 
moved only at 20, 40 and 60min. Condition 3 involved no Transwell® insert moving and 
CP20 concentrations were only determined at the last time point of 60min.  
 
The time-dependent transport of CP20 almost follows a straight line as shown in 
Figure 18, which may suggest that CP20 transport across the PBEC monolayer is via non-
facilitated diffusion. 
After 20min 6.36 ± 2.02% of CP20 were determined in the basolateral chamber for 
PBECs under experimental condition 1 and 11.79 ± 1.23% for PBECs under experimental 
condition 2. After 40min, the amount of CP20 transferred was 13.30 ± 2.61% and 22.13 ± 
2.18% for conditions 1 and 2 respectively.  
 
Figure 18: Time dependent transfer of 800μM CP20 across the PBEC 
monolayer.  
Transfer of CP20 is expressed in mg for 3 experimental conditions (explanation 
in the text). 
Data is represented as mean ± SEM (n=3). 
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After 60min, 20.60 ± 3.06% of CP20 was transferred into the basolateral chamber for 
PBECs in experimental condition 1, whereas similar concentrations were found for 
conditions 2 and 3 (32.32 ± 2.79% and 31.31 ± 0.28% respectively). 
 
Moving the Transwell® inserts during the permeability assay was found to affect the 
transport of CP20 across the PBEC monolayer, as the more the filter inserts were moved 
the more CP20 permeability decreased as seen in Figure 18 and Figure 19. 
At 20min and 40min no statistically significant difference in CP20 transfer was found 
when comparing experimental condition 1 and 2. However, after 60min, when the filter 
inserts were moved for the sixth time in case of PBECs in experimental condition 1, a 
significant difference was observed between conditions 1 and 2, as well as when 
comparing the experimental conditions 1 and 3.  
These results confirmed that there is sufficient transfer of CP20 into the basolateral 
chamber after an assay time of 20min, hence 20min could be used as the end time point 
for the in vitro permeability assays. 
Furthermore, these results suggested that the permeability assays should be conducted 
without any moving of the Transwell® inserts to reduce variability and therefore all 
further experiments were carried out using only a single end time point. 
 
Figure 19: Transfer of CP 20 expressed in mg, for the 3 
experimental conditions (explanation in the text) after 
20min, 40min and 60min.  
Data is represented as mean ± SEM (n=3). 
*  p< 0.05  
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3.3 Relationship between TEER and sodium fluorescein 
permeability 
 
 
The relationship between the value of TEER and the permeability of the paracellular 
marker sodium fluorescein could be shown to be non-linear (Figure 20), as has been 
described in the literature by Gaillard and de Boer (2000). This becomes evident when 
looking at what influences the permeability of sodium fluorescein and the value of TEER. 
Transport of solutes depends on the sum of transport across all junctional pathways, 
therefore areas with leakier tight junctions will be averaged out by areas with tighter tight 
junctions. Contrary to that, in the case of the electrical resistance over the monolayer 
(TEER), the value is essentially determined by areas with the lowest resistance, even 
though these areas exist at a lower density (Gaillard and de Boer, 2000). 
 
Figure 20: Relationship between TEER and sodium fluorescein 
transfer with fitted curves for each of the 3 culture conditions and 
for the pooled data from all culture conditions (n=78). 
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3.4 Influence of the culture condition 
PBECs were grown under 3 different culture conditions (2.2.3.1) and the effect of the 
culture condition on the quality of the monolayer was investigated. For this purpose the 
differences in the value of TEER and the permeability of the paracellular marker sodium 
fluorescein were assessed. 
3.4.1 Influence on TEER 
 
 
PBECs treated with astrocyte-conditioned media and PBECs grown in co-culture with C6 
glioblastoma showed improved electrical resistance over the PBEC monolayer compared 
to PBECs that were grown in monoculture (Figure 21). PBECs in monoculture displayed 
TEER values of 29.41 ± 5.82 Ω.cm2, whereas PBECs in monoculture, that had 
additionally been treated with astrocyte-conditioned media, displayed TEERs of 
31.79 ± 10.79 Ω.cm2. Co-culture with C6 glioblastoma affected electrical resistance the 
 
Figure 21: Electrical resistance over the PBEC monolayer 
expressed in Ω.cm2, shown for each of the 3 culture 
conditions: 
mono PBECs grown in monoculture 
ACM  PBECs grown in monoculture and treated with 
 astrocyte-conditioned media 
C6 co PBECs grown in co-culture with C6 glioblastoma 
Data is represented as mean ± SEM (n=22-27). 
Difference from control: * p< 0.05 
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most, as it increased by 67% to 49.19 ± 6.29 Ω.cm2 compared to PBECs grown in 
monoculture. 
3.4.2 Influence on sodium fluorescein permeability 
 
 
Treatment with astrocyte-conditioned media as well as co-culture with C6 glioblastoma 
was found to effect sodium fluorescein permeability of the PBEC monolayer (Figure 22). 
Both conditions significantly decreased sodium fluorescein permeability compared to 
PBECs grown in monoculture. PBECs in monoculture demonstrated a sodium fluorescein 
transfer of 11.85 ± 1.16%, whereas PBECs that had been treated with astrocyte-
conditioned media showed a sodium fluorescein permeability of 9.16 ± 1.23%. The 
greatest effect was found for PBECs grown in co-culture with C6 glioblastoma, where 
sodium fluorescein transfer decreased by 52% to a permeability of 5.63 ± 1.04% 
compared to sodium fluorescein permeability of PBECs grown in monoculture. 
 
Figure 22: Sodium fluorescein permeability in percent, 
shown for each of the 3 culture conditions: 
Mono PBECs grown in monoculture 
ACM PBECs grown in monoculture and treated with 
astrocyte-conditioned media 
C6 co PBECs grown in co-culture with C6 glioblastoma 
Data is represented as mean ± SEM (n=22-27). 
* p< 0.05 / ** p< 0.01/  *** p< 0.001 
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3.5 Permeability assay 
3.5.1 HPO transfer 
Transfer of 800μM HPO from the apical to the basolateral chamber across the PBEC 
monolayer was studied in the permeability assay and HPO concentrations were 
determined after 20mins using HPLC. After analysis of the data, monolayers with TEER 
values below 40 Ω.cm2 were considered not high enough and consequently excluded from 
the following data. The average TEER value of PBEC monolayers represented in the 
graphs below was 81.48 Ω.cm2. 
 
The overall transfer across the PBEC monolayer is expressed in percent and shown in 
Figure 23. This includes transfer into the basolateral chamber via the transendothelial 
cellular route as well as transfer via the paracellular route. Thus, HPO transfer had to be 
corrected for paracellular movement due to leaky tight junctions using the data acquired 
from the permeability of the paracellular marker sodium fluorescein. As a result of that, 
the data for corrected HPO transfer is shown in Figure 24. 
 
Figure 23: HPO overall transfer in percent across the 
PBEC monolayer (further explanation in the text). 
Data is pooled from all culture conditions and 
represented as mean ± SEM (n=2-5). 
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All HPOs were able to cross the blood-brain barrier in the in vitro assay. Compounds 
YMF 16 and CP20 showed the highest in vitro BBB permeability with 7.17 ± 1.36% and 
6.98 ± 1.05% respectively. YMF 25 demonstrated the lowest ability to cross the PBEC 
monolayer with a permeability of 3.31 ± 1.34%. Nevertheless, statistically no significant 
difference was found between the permeability of these HPOs. 
3.5.2 In vivo – in vitro correlation 
The aim of this study was to investigate whether a correlation between in vitro and in vivo 
blood-brain barrier permeability could be established, that would allow predictions of in 
vivo permeability to be made from in vitro data. For this purpose the data acquired from 
the in vitro permeability assays was plotted against in vivo permeability determined by 
Roy (2009). 
 
 
 
 
 
 
Figure 24: HPO transfer across the PBEC monolayer 
corrected for paracellular transport, expressed in 
percent (further explanation in the text). 
Data is pooled from all culture conditions and 
represented as mean ± SEM (n=2-5). 
45 
 
 
 
 
 
 
 
 
 
 
There was no correlation found between in vivo and in vitro HPO blood-brain barrier 
permeability (R
2 
= 0.38) (Figure 25). 
3.5.3 Intracellular accumulation 
In addition to determining HPO concentrations in the basolateral chamber after 20min, 
HPO concentrations in the apical chamber was also quantified in order to calculate 
intracellular accumulation. 
 
 
 
Figure 25: Correlation between in vivo and 
in vitro HPO blood-brain barrier 
permeability. 
 
Figure 26: Calculated intracellular HPO accumulation 
in percent. 
Data is pooled from all culture conditions and 
represented as mean ± SEM (n=2-5). 
 
Figure 27: Correlation between calculated 
intracellular accumulation and logD7.4. 
R
2
 = 0.43 
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Despite the lack of a statistically significant difference between the intracellular 
accumulation of the HPOs (Figure 26), a trend (R
2
 = 0.43) could be observed when 
intracellular accumulation was plotted against the lipophilicity (logD7.4) of the HPOs 
(Figure 27). 
3.5.4 Transfer + intracellular accumulation and in vivo – in vitro 
correlation 
Taking into account the trend observed in intracellular accumulation between the HPOs, 
values of intracellular accumulation were added to values of transfer across the PBEC 
monolayer to be able to better distinguish between the HPOs. As a result, transfer added 
to intracellular accumulation served as a measure of their ability to penetrate into and 
across the PBECs in the in vitro permeability assay.  
 
The data for the combined values of intracellular accumulation and transfer across the 
monolayer is shown in Figure 28. The order of the HPOs changed greatly compared to 
their order in the data for HPO transfer alone (Figure 24). According to the combined 
data, compounds YMF 24 and YMF 25 demonstrated the highest ability to penetrate into 
and across the PBEC monolayer, whereas compound YMF 16 showed the lowest. 
 
Figure 28: Combined values of HPO transfer and 
calculated intracellular accumulation in percent. 
Data is pooled from all culture conditions and 
represented as mean ± SEM (n=2-5). 
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The combined data was then plotted against HPO in vivo permeability, where a good 
correlation between the combined in vitro data and the in vivo data could be established 
with a R
2
 of 0.79 and a p value of 0.0176. 
3.5.5 Permeability vs. logD7.4 and MW  
Since the physicochemical properties of a compound essentially influence its ability to 
cross the blood-brain barrier, the effects of molecular weight and lipophilicity (logD7.4) on 
blood-brain barrier permeability of the HPOs used in this study was evaluated for both in 
vitro and in vivo data. The combined value of transfer across the endothelial cell 
monolayer added to calculated intracellular accumulation was used as the in vitro 
permeability. 
 
 
 
 
 
Figure 29: Correlation between in vitro (transfer + 
intracellular accumulation) and in vivo HPO 
transfer. 
48 
 
 
 
There was no correlation found between the molecular weight of the HPOs and the blood-
brain barrier permeability, neither in the case of the in vitro nor the in vivo data 
(Figure 30, Figure 31).Contrary to the molecular weight, a correlation between the logD7.4 
and the blood-brain barrier permeability was confirmed for the HPOs used in this study. 
In vivo blood-brain barrier permeability data correlated significantly with logD7.4 of the 
HPOs with R
2
 = 0.81 (Figure 33) compared to the in vitro correlation with R
2
 = 0.50 
(Figure 32). 
 
Figure 32: logD7.4 plotted against in vitro HPO 
transfer added to intracellular accumulation 
(expressed in percent). 
R
2
 = 0.50 
 
Figure 33: logD7.4 plotted against in vivo HPO 
transfer (expressed in percent). 
R
2
 = 0.81 
Figure 30: Molecular weight (MW) plotted 
against in vitro HPO transfer added to 
intracellular accumulation (expressed in 
percent). 
Figure 31: Molecular weight (MW) plotted 
against in vivo HPO transfer (expressed in 
percent). 
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3.6 HPLC 
The HPOs showed a single, sharp peak in the chromatogram with retention times between 
10-13min. Sample chromatograms and standard curves for all HPOs are shown in the 
appendix (9.1, 9.2). 
Compound YMF 29 showed 3 separate peaks in its chromatogram, therefore mass 
spectrometry (MS) was applied to investigate whether this was the result of compound 
degradation. MS confirmed that YMF 29 had not degraded (spectrum shown in appendix 
9.3), thus the biggest peak at a retention time of 10min was used to base the standard 
curve upon and to calculate concentrations from the permeability assay samples.  
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4 DISCUSSION 
Iron chelation therapy is a promising new therapeutic approach in the treatment of 
neurodegenerative diseases like Parkinson’s disease, Alzheimer’s disease or Friedreich’s 
Ataxia. Hydroxypyridinones (HPOs) have been identified as suitable iron chelators and 
the orally active iron chelator CP20 (deferiprone) has already been shown to be able to 
cross the blood-brain barrier (BBB) (Hider et al., 2011). Hence analogues of CP20 were 
synthesized and in vivo experiments were carried out on guinea pigs using the in situ 
brain perfusion technique to determine BBB permeability of these HPOs (Roy, 2009). 
Although in vivo experiments provide valuable information, the fact that they are both 
cost and labour intensive fuel the search for other models to test BBB permeability. Thus, 
an in vitro assay could represent a good alternative to in vivo experiments. In addition, an 
in vitro assay would potentially allow for predictions of in vivo BBB permeability to be 
made from the in vitro data. Consequently, an in vitro assay could serve as an initial 
screening in the process of designing and synthesizing new HPOs. 
To develop such an in vitro assay, primary porcine brain endothelial cells were used in 
this study. Furthermore, the same concentration (800µM), as well as the same end time 
point (20min), that had been used to perform the in vivo experiments, was applied in 
order to accurately compare the in vitro and in vivo data. 
4.1 In vitro system 
A good BBB in vitro model should represent the situation found in vivo as closely as 
possible in regard to the specific characteristics of the BBB (1.2.2). When performing 
transport studies, the formation of a sufficiently tight monolayer, which expresses high 
electrical resistance and a low permeability to marker molecules, is the primary goal in 
the establishment of the BBB in vitro model. However, the loss of characteristic 
properties of primary brain endothelial cells when cultured in vitro presents a problem 
and various approaches have been studied to enhance tight junction formation including 
the use of hydrocortisone, serum free media, cAMP and the influence of astrocytes 
(Hoheisel et al., 1998; Rubin et al., 1991). 
Therefore, the influence of different culture conditions on the integrity of the PBEC 
monolayer was investigated in this study. PBECs were subjected to 3 different culture 
51 
 
 
conditions, as they were either grown in monoculture, in the presence of astrocytic factors 
(astrocyte-conditioned media (ACM), taken from cultured primary rat astrocytes) or in 
non-contact co-culture with C6 glioblastoma. PBECs grown in monoculture served as a 
control to evaluate the results. As shown in the results (3.4), TEER for PBECs treated 
with ACM increased by 8% while co-culture with C6 glioblastoma increased the value of 
TEER by 67%. In addition, the permeability of sodium fluorescein could be significantly 
decreased by 22% in the case of PBECs treated with astrocyte conditioned media and 
52% in the case of PBEC/C6 glioblastoma co-culture. 
These results show that astrocytes influence the barrier properties in vitro and tightness of 
the barrier can be improved by using conditioned media or co-culture. However, co-
culture with C6 glioblastoma was found to have a greater effect on both the value of 
TEER and the permeability of sodium fluorescein, suggesting that the influence of 
astrocytes on barrier integrity is not only mediated by soluble factors. A close contact that 
allows for constant interchange seems to further positively affect the quality of the 
monolayer in regard to tight junction formation. Thus, the closer the culture conditions 
are to conditions present in vivo, the better the tight junctions are at restricting 
paracellular movement across the PBEC monolayer, represented by an increase in TEER 
and a decrease in sodium fluorescein permeability. 
These findings are in general agreement with other published studies, though the degree 
of improved barrier tightness varied between the present study and the previously 
published ones, but also varied greatly among the published data. For example, Zhang et 
al. (2006) found that PBECs treated with ACM from primary astrocytes increased the 
TEER by 10-25% and Smith et al. (2007) showed that PBECs treated with ACM from C6 
glioblastoma resulted in an increase in TEER by a factor of 5 and co-culture with C6 
glioblastoma by a factor of 10. The average TEER displayed by PBECs used for 
experiments in this study was 81.48 Ω.cm2. However, Franke et al. (2000) developed a 
model with PBECs that reached TEERs of 700 Ω.cm2, peak resistance even reached 
1500 Ω.cm2, without the influence of astrocytes. Zhang et al. (2006) also reported higher 
TEER values (300-550 Ω.cm2) when PBECs were treated with ACM. Contrary to these 
findings, in the study of Jeliazkova-Mecheva and Bobilya (2003), PBECs grown in 
monoculture reached average TEERs of only 28 Ω.cm2, but TEER value could be 
increased when PBECs received treatment with ACM to above 100 Ω.cm2. 
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Keeping in mind that transport studies are aimed to be performed on the PBEC 
monolayers, a sufficiently tight barrier needs to be formed in order to accurately 
distinguish between low permeability compounds. Gaillard and de Boer (2000) showed 
that the relationship between the value of TEER and the permeability of sodium 
fluorescein was not linear. Monolayers with a TEER value above 131 Ω.cm2 were 
determined suitable for performing transport experiments, since above this value, sodium 
fluorescein permeability was shown to be independent of a further increase in TEER. This 
non-linear relationship was also observed in the present study (Figure 20), but the 
threshold value of 131Ω.cm2 could not be reached for the majority of the monolayers. 
However, monolayers used for the first experiments with CP20 (time-dependent 
transport) reached peak resistances of up to 240 Ω.cm2. 
Interestingly, CP20 permeability in these experiments was 9.08% compared to 6.98% in 
the permeability assays performed afterwards with PBEC monolayers that displayed 
much lower TEERs (average TEER used for experiments with CP20: 107 Ω.cm2) and a 
much higher sodium fluorescein permeability (negligible sodium fluorescein permeability 
in the time-dependent experiments with CP20). This suggests that correcting the 
permeability value for paracellular transport using the sodium fluorescein data, may be a 
good approach to correct for leakier tight junctions, since statistically (unpaired, two 
tailed t-test) these results are not different from the results obtained from PBEC 
monolayers, which demonstrated sufficient TJ formation for performing experiments. 
Although these results lack statistical difference, correcting data from PBEC monolayers 
with leaky tight junctions apparently underestimated the permeability of CP20. When 
monolayers don’t form tight TJ (high sodium fluorescein permeability), it cannot be 
guaranteed that exactly the same fraction of CP20 is transferred into the basolateral 
chamber via the paracellular route as is the case for sodium fluorescein, where the only 
known route of transfer into the basolateral chamber is the paracellular one. Therefore it 
seems reasonable that a correction based on this assumption could easily overestimate the 
paracellular proportion of CP20 transport and hence underestimate the “real” transfer, 
which is via the transendothelial cellular route. Consequently, future work should be 
directed towards being able to cultivate PBECs with sufficiently tight monolayers and 
thus negligible sodium fluorescein permeability. 
Despite this, the underlying problem of culturing primary brain endothelial cells remains - 
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batch to batch reproducibility. Biological variations and tissue quality are one of the main 
obstacles when developing a reproducible BBB in vitro model, considering that every 
brain used to isolate endothelial cells is different from the next. This may explain the low 
TEER values demonstrated by the PBECs used for this study, since in the same research 
group PBECs from previous isolations displayed TEERs of up to 800 Ω.cm2. 
4.2 In vivo – in vitro correlation 
Apart from the problems encountered with primary cell culture, future work might have 
to focus on improving the in vitro assay as well. The main objective for this study was to 
develop an in vitro assay to make it possible to correlate in vivo and in vitro data. 
However, no correlation was found when in vivo and in vitro permeability was plotted 
(Figure 25). Interestingly, a difference in intracellular accumulation between the HPOs 
was found and, despite the lack of a statistically significant difference, a trend could be 
observed when intracellular accumulation and lipophilicity (logD7.4) were plotted 
(Figure 27). This suggests that the higher the lipophilicity of the HPO, the more it was 
retained in the cell monolayer. Since penetrating into the endothelial cells is the first step 
for the HPOs to cross the endothelial cell layer (blood-brain barrier) and reach the 
basolateral chamber (brain), this observation was essential. Therefore, the values of 
intracellular accumulation were added to the values of transfer across the PBEC 
monolayer and subsequently served as a measure of their ability to penetrate into and 
across the PBEC monolayer. As a result, it was possible to establish a good correlation 
(R
2
 = 0.79) between the in vivo and in vitro blood-brain barrier permeability (Figure 29). 
Thus, a longer end time point might be needed when performing the in vitro assay in 
order to ensure that the HPOs retained in the cell layer are able to cross into the 
basolateral chamber.  
Moreover, the effect of the unstirred water layer in vitro may have to be considered since 
in vivo there is virtually no unstirred water layer due to a mixing effect of circulating 
erythrocytes (Youdim et al, 2003). On the contrary, the unstirred water layer present in in 
vitro experiments has been shown to influence in vitro permeability, as it can be a rate 
limiting factor (Avdeef, 2010; Zhang et al., 2006). As a consequence, the in vitro assays 
may have to be carried out at stirring rate higher than 200rpm, which was used during the 
experiments in this study, as for example Zhang et al. (2006) applied 600rpm. However, 
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when applying higher stirring rates, the fragility of primary endothelial cells needs to be 
considered carefully (Avdeef, 2010). Thus, there is a need of further research in order to 
determine a stirring rate that sufficiently decreases the effect of the unstirred water layer 
but at the same time does not affect the barrier integrity. 
4.3 Influence of structural features on BBB permeability 
The HPOs used in this study were designed as close analogues of deferiprone (CP20) 
with regard to oral availability and iron chelation ability, but with the aim to have an 
enhanced BBB permeability. The effect of increasing molecular weight (longer N-alkyl 
substitution) and the introduction of a fluorine atom on the pyridine ring were to be 
investigated (Roy, 2009). 
It was found that lipophilicity correlated with BBB permeability, both in vitro and in vivo 
(Figure 32, Figure 33), but no correlation was found between the molecular weight and 
BBB permeability. This might be due to a limited range of molecular weights displayed 
by the HPOs selected for this study (Table 1). When looking closely at the structures of 
the selected HPOs, interesting observations can be made. Compounds YMF 8 and 
YMF16, as well as compounds YMF 24 and YMF 25 have the same molecular weight, 
but differ in the position of the fluorine atom on the pyridinone ring. In the case of YMF 8 
and YMF 24, the pyridinone ring is substituted with the fluorine at position 2, whereas in 
the case of YMF 16 and YMF 25 the fluorine is at position 5 of the pyridinone ring. It 
was found that the position of the fluorine on the ring affected lipophilicity (logD7.4) and 
may subsequently also influence BBB permeability.  
 
Figure 34: Structure of YMF 8, YMF 16, YMF 24 and YMF 25. Intramolecular hydrogen bonds 
shown for YMF 8 and YMF 24 
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An intramolecular hydrogen bond is most likely able to form between the fluorine in 
position 2 and the 3-hydroxyl hydrogen (Figure 34). This causes the fluorine to be less 
available for hydrogen bonding with the solvent, subsequently making these HPOs more 
lipophilic compared to HPOs with fluorine substitution in position 5. This effect may be 
responsible for the higher BBB permeability found for YMF 8 and YMF 24 compared to 
YMF 16 and YMF 25 respectively. 
Furthermore, it is noticed that YMF 29 was found to have a higher BBB permeability 
than would be predicted from its logD7.4. This observation could be made for the in vitro 
(Figure 35) data, but more clearly for the in vivo data (Figure 36). 
 
Structurally, YMF 29 differs from the other CP20 analogues. An additional amide moiety 
was introduced to the pyridinone ring at position 5, though YMF 29 also has a fluorine 
substitution at position 2, like YMF 8 and YMF 24. This amide substitution is responsible 
for YMF 29 hydrophilic properties, however, it may also be responsible for the enhanced 
ability of YMF 29 to cross the BBB compared to the more lipophilic HPOs. Its high BBB 
permeability in regard to its lipophilicity, is most likely due to an intramolecular hydrogen 
bond that can be formed between the amide functionality and the carbonyl oxygen 
(Figure 37). 
Figure 35: logD7.4 plotted against HPO 
in vitro transfer added to intracellular 
accumulation (expressed in percent). 
The arrow points out the dot that 
represents YMF 29. 
Figure 36: logD7.4 plotted against HPO 
in vivo permeability (expressed in 
percent). The arrow points out the dot 
that represents YMF 29. 
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Figure 37: Structure and intramolecular  
hydrogen bonds of YMF 29 
 
Moreover, the fluorine in position 2 may be able to form an intramolecular hydrogen 
bond with the 3-hydroxy hydrogen as discussed for YMF 8 and YMF 24. The fact that 
both hydrogen atoms, otherwise available for intermolecular hydrogen bonding with other 
molecules, are involved in these intramolecular hydrogen bonds, positively influence the 
compounds ability to permeate membranes (Roy, 2009). Additionally, the intramolecular 
hydrogen bonds make YMF 29 completely planar, which further assists the compound in 
successfully crossing membranes. Consequently, when designing BBB permeable HPOs, 
structural features similar to those of YMF 29 could be useful. 
4.4 Toxicity and neuroprotection 
Although BBB permeability is a key quality for HPOs that can potentially be used for the 
treatment of neurodegenerative diseases, the possibly toxic effects on endothelial cells, 
neurons and other brain cells must not be neglected. Moreover, the HPOs should provide 
neuroprotection against insults involving iron. 
In order to determine the effect of HPOs on endothelial cell viability, toxicity assays were 
performed on PBECs and the results showed that YMF 8, YMF 16 and YMF 24 affected 
cell viability after 2 hours, with about 76-82% of cells remaining viable. For CP20 no 
toxic effect on PBECs was found. For the treatment of transfusional iron overload in 
patients suffering from ß-Thalassaemia, CP20 (deferiprone) is administered at a 
concentration of 25-100mg/kg (180-720µM) (Hoffbrand et al., 2003), which is lower 
compared to the concentration used in the present study (800µM). In a previous study, 
toxicity assays using mouse embryonic cortical neurons showed that neither CP20 nor 
YMF 24, YMF 25 or YMF 29 had an effect on neuronal cell viability at the 
57 
 
 
concentrations of 10µM, 30µM and 100µM over an incubation time of 24 hours (Roy, 
2009). The concentrations used on the cortical neurons, again were much lower than the 
concentration used on PBECs, though the incubation time was longer. Consequently, 
there may be a need for further investigation on the toxicity of the CP20 analogues on 
PBECs. 
What is more, in a recent study, the neuroprotective abilities against various insults (ferric 
nitrilotriacetate, H2O2 and Aβ(1-40)) on cultured cortical neurons could be shown for 
CP20 (Molina-Holgado et al., 2008). Moderate ability to demonstrate neuroprotection 
against these insults was found for YMF 24 and YMF 25, whereas superior to equal 
neuroprotective efficiency was demonstrated for YMF 29 compared to CP20 (Roy, 2009). 
4.5 Clinical use 
In a clinical trial with patients suffering from Friedreich’s Ataxia, CP20 (deferiprone) was 
shown to demonstrate beneficial effects (Boeddard et al., 2007). Moreover, deferiprone is 
currently under investigation in a clinical trial for the treatment of Parkinson’s disease.  
Due to their small size and non-charged nature, the HPOs can cross the BBB and the 
route of transfer is most likely passive diffusion (Hider et al., 2011), which could also be 
observed in the present study (Figure 18). However, non-facilitated diffusion clearly 
limits the maximum flux of the HPO into the brain, which may require a more efficient 
targeting mechanism in order to enhance their BBB permeability (Hider et al., 2011). A 
potential approach could be the use of nanoparticles, which can use different address 
systems such as the melanotransferrin receptor, the transferring receptor and the 
apolipoprotein receptor. These nanoparticles may also be able to recross into the 
bloodstream, but on the other hand would have to be administered parenterally (Hider et 
al., 2011). 
An alternative approach to enhance BBB permeability could be the use of sugar 
conjugates, which would make it possible to administer the drug orally. The fact that there 
is a high expression of the glucose transporter GLUT-1 at the BBB would facilitate the 
entry of the HPO-sugar conjugate into the brain. Moreover, its hydrophilic properties 
would limit liver first pass effects. Despite this, the O-glycosylated deferiprone was found 
not to cross the BBB in a recent study (Roy et al., 2010). 
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5 ABSTRACT  
Oxidative stress and protein aggregation have been shown to play a key role in the 
pathology of neurodegenerative diseases like Alzheimer’s disease and Parkinson’s 
disease. Moreover, high levels of metals like iron have been found to accumulate in the 
brain, which may provide the link between oxidative stress, protein aggregation and 
neurodegeneration. Iron chelation is a promising new therapeutic strategy for the 
treatment of these diseases and 3-hydroxypyridin-4-ones (HPO) have been identified as 
suitable chelators. In order to chelate the labile iron present in the brain, the iron chelator 
must be able to cross the blood-brain barrier (BBB), rendering the assessment of BBB 
permeability an essential task. Since in vivo experiments are both labour and cost 
intensive, an in vitro assay could serve as a good alternative. Thus, the aim of this study 
was to develop an in vitro assay to determine the BBB permeability of the selected HPOs 
and to correlate the acquired in vitro data with in vivo data that was already available. 
Such a correlation would then allow for predictions of in vivo BBB permeability to be 
made from in vitro data, which could be quite beneficial in the process of designing and 
synthesizing new HPOs. Primary porcine brain endothelial cells (PBEC) were used in this 
study and transport across the cell monolayer was studied using a Transwell® system. 
PBECs were subjected to 3 different culture conditions in order to evaluate different 
approaches to enhance barrier integrity in vitro. Moreover, the effect of the HPOs on 
PBEC viability was investigated. All the selected HPOs were able to cross the BBB in 
vitro and a good correlation was found between the in vitro and the in vivo BBB 
permeability, when HPO transfer added to the value of intracellular accumulation was 
used as a measure of in vitro BBB permeability. 
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6 ZUSAMMENFASSUNG 
Oxidativer Stress und Proteinaggregation spielen eine wichtige Rolle in der Pathogenese 
von neurodegenerativen Erkrankungen wie der Alzheimer- und der Parkinson- Krankheit. 
Darüber hinaus konnte die Akkumulation von Metallen wie Eisen im Gehirn von 
Erkrankten nachgewiesen werden, was möglicherweise den Zusammenhang zwischen 
oxidativem Stress, Proteinaggregation und Neurodegeneration herstellt. Eisenchelation ist 
daher eine neue, vielversprechende therapeutische Strategie um diese Krankheiten zu 
behandeln und 3-Hydroxypyridin-4one (HPO) stellen passende Chelatoren für diese 
Anwendung dar. Um das labile Eisen im Gehirn zu chelatieren, muss der Eisenchelator 
die Fähigkeit besitzen, die Blut-Hirnschranke zu überwinden. Daher ist das Bestimmen 
der Blut-Hirnschranken-Permeabilität ein wichtiger Schritt. In vitro Experimente könnten 
hierbei eine gute Alternative zu arbeits- und kostenintensiven in vivo Experimenten 
darstellen. Demzufolge war das Ziel dieser Diplomarbeit einen in vitro Assay zu 
entwickeln, um die Blut-Hirnschranken-Permeabilität von ausgewählten HPOs zu 
bestimmen und diese mit schon vorhandenen in vivo Daten zu korrelieren. Solch eine 
Korrelation würde das Vorhersagen von in vivo Permeabilität an Hand von in vitro Daten 
ermöglichen, was besonders für die Entwicklung und Synthese von neuen HPOs 
vorteilhaft wäre. Primäre porzine Gehirn-Endothelzellen (PBEC) wurden für den in vitro 
Assay verwendet und der Transport der HPOs durch den Zellmonolayer mit Hilfe eines 
Transwell® Systems untersucht. Die PBECs wurden unter 3 verschiedenen Bedingungen 
kultiviert, um die Evaluierung verschiedener Methoden zur Verbesserung der 
Barrierenfunktion in vitro zu ermöglichen. Alle getesteten HPOs konnten im in vitro 
Assay die Blut-Hirnschranke überwinden. Eine gute Korrelation zwischen in vitro und in 
vivo Permeabilität konnte gezeigt werden, sobald HPO-Transfer addiert zu der 
Konzentration an intrazellulär verbleibenden HPOs als Maß für die in vitro Permeabilität 
herangezogen wurde. 
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9 APPENDIX 
9.1 HPO standard curves 
 
Figure 38: Standard curve CP20 
 
 
 
Figure 39: Standard curve YMF 8 
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Figure 40: Standard curve YMF 16 
 
 
 
Figure 41: Standard curve YMF 24 
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Figure 42: Standard curve YMF 25 
 
 
 
Figure 43: Standard curve YMF 29 
y = 6E+07x + 127063 
R² = 0,999 
0 
10000000 
20000000 
30000000 
40000000 
50000000 
60000000 
70000000 
0,000 0,200 0,400 0,600 0,800 1,000 1,200 
y = 1E+07x - 32466 
R² = 0,9997 
0 
2000000 
4000000 
6000000 
8000000 
10000000 
12000000 
14000000 
0,000 0,200 0,400 0,600 0,800 1,000 1,200 
71 
 
9.2 HPLC chromatograms 
 
 
Figure 44: HPLC chromatogram CP20 (1mM), 100µL injection 
 
 
 
Figure 45: HPLC chromatogram YMF 8 (1mM), 100µL injection 
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Figure 46: HPLC chromatogram YMF 16 (1mM), 100µL injection 
 
 
 
 
Figure 4726: HPLC chromatogram YMF 24 (1mM), 100µL injection 
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Figure 27: HPLC chromatogram YMF 25 (1mM), 100µL injection 
 
 
 
Figure 28: HPLC chromatogram YMF 29 (1mM), 100µL injection 
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9.3 YMF 29 mass spectrometry 
 
Figure 29: ESI MS(+ve) of YMF 29 (MW 267; YMF 29 – HBr: MW 187),  20µL of sample diluted to 1mL with 0.1% FA in 50% MeOH 
M16972 #215-300 RT: 2.05-2.56 AV: 54 NL: 1.88E8
F: + p ESI Full ms [50.00-500.00]
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